• Corpus ID: 1470288

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

  title={Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.},
  author={David L. Emerson and Raymond A. Bendele and Eric N. Brown and Soong T. Chiang and John Desjardins and Larry Dihel and Stanley C. Gill and Marta Hamilton and J D Leray and Lotus Moon-Mcdermott and K Moynihan and Frank C. Richardson and Blake E. Tomkinson and Michael Joseph Luzzio and David P. Baccanari},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={6 7},
  • D. EmersonR. Bendele D. Baccanari
  • Published 1 July 2000
  • Biology, Chemistry
  • Clinical cancer research : an official journal of the American Association for Cancer Research
Lurtotecan is a clinically active water-soluble camptothecin analogue that has been formulated into a low-clearance unilamellar liposome, NX 211. Comparative studies between free drug and NX 211 have been performed assessing pharmacokinetics in nude mice, tissue distribution in tumor-bearing mice, and antitumor efficacy in xenografts. Compared with lurtotecan, NX 211 demonstrated a significant increase in plasma residence time and a subsequent 1500-fold increase in the plasma area under the… 

Figures and Tables from this paper

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

Findings are one of the keys justifying the development of a liposomal formulation of lurtotecan, which has the intent to increase tumor exposure and increase antitumor efficacy.

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

Pharmacologic data suggest a relationship between exposure to lurtotecan and NX 211-induced clinical effects and the recommended dose for phase II studies is 3.8 mg/m(2) once every 3 weeks.

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

  • A. Ko
  • Medicine, Biology
    International journal of nanomedicine
  • 2016
Nanoliposomal irinotecan represents an important landmark in cancer drug development, and potentially ushers in a new era where a greater number of patients with advanced pancreatic cancer can be sequenced through multiple lines of therapy translating into meaningful improvements in survival.

Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution

The aim of this study was to perform a mechanistic study of the incorporation and retention of the lipophilic parent CPT compound in different liposome formulations using radiolabeled CPT and thus to be able to identify promising CPT delivery systems.

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity.

Treatment of 9L Gliosarcoma in Rats by Ferrociphenol-Loaded Lipid Nanocapsules Based on a Passive Targeting Strategy via the EPR Effect

The results demonstrate the interesting perspectives for the systemic treatment of glioma thanks to bio-organometallic chemotherapy via lipid nanocapsules via lipid nanoparticles loaded with ferrociphenol, FcdiOH.

Liposomal Quercetin Efficiently Suppresses Growth of Solid Tumors in Murine Models

The data indicated that pegylated liposomal quercetin can significantly improve the solubility and bioavailability of quERCetin and can be a potential application in the treatment of tumor.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

The modular organization of immunoliposome technology enables a combinatorial approach in which a repertoire of monoclonal antibody fragments can be used in conjunction with a series of liposomal drugs to yield a new generation of molecularly targeted agents.



Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.

Comparisons of drug and liposomal lipid accumulation in tumour and muscle tissue indicate that the enhanced efficacy ofliposomal vincristine is related predominantly to drug delivered by liposomes to the tumour site rather than drug released from liposome in the circulation.

Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.

  • G. ColbernD. Dykes P. Working
  • Biology, Chemistry
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
Despite the increased toxicity seen with SPI-355, the therapeutic index of the liposomal formulation was increased approximately 5-fold over that of nonliposomal GL147211C, suggesting that such a pegylated liposome formulation could demonstrate increased therapeutic index in human patients.

Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.

Both types of liposomes reduced considerably the amount of drug accumulating in the heart compared with that accumulating after injection of free DXR, and peak drug concentrations in the liver were observed in agreement with the plasma clearance curves.

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.

The survival and histopathological data presented suggest that, with regard to a group of neoplastic conditions with a predominant pattern of liver dissemination, a substantial increase in the therapeutic index of Adriamycin can be achieved in a selective manner with the use of liposomes.

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

  • P. GillB. Espina A. Levine
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
DaunoXome can be given safely at doses up to 60 mg/m2 every 2 weeks and has significant antitumor activity in patients with AIDS-KS and has an improved pharmacokinetic profile compared with free daunorubicin, and is well tolerated.

Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).

Some of the benefits associated with the use of PEG-modified liposomes, such as increased blood levels and enhanced circulation lifetime, may be of little advantage in terms of maximizing liposomal drug accumulation in sites of tumor growth.

Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

The demonstration of enhanced antineoplastic activity and an increased tolerance for daunorubicin suggests that this specific SUV composition may be an effective delivery system for a wide range of chemotherapeutic agents in the treatment of solid tumors.

Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.

It is reported here that liposomes can alter the in vivo disposition of an entrapped drug not only on a macroscopic but also on a microscopic scale, suggesting that Liposmal daunorubicin can provide sustained intracellular levels of the drug within the tumor.

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

By selective changes in lipid composition, up to a 60-fold increase in the fraction of recovered dose present in blood 24 hr after i.v. injection is achieved, which has considerable therapeutic potential in cancer for increasing the concentration of cytotoxic agents in tumors while minimizing the likelihood of toxicity to the reticuloendothelial system.

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.